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Abstract
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with
relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received
Bendamustine (90mg/m2, day 1+2) and Rituximab (375mg/m2, day 1) with Temsirolimus in doses from 25 to 75mg in phase I and
50mg Temsirolimus in phase II, added on day 1, 8, 15 of a 28 days cycle. The primary endpoint of the phase II was ORR at the end of
treatment. Overall, 39 (29 MCL, 10 FL) patients were included. Median age was 71 years and median pretreatment number was 2.
Grade 3/4 non-hematologic adverse events were rare and included hyperglycemia in 3 patients (7%) and angioedema in 2 patients
(5%). Infectious complications grade 3/4 were observed in 9 patients (23%). Hematologic grade 3/4 events included leukopenia in 22
(56%), neutropenia in 18 (46%), lymphopenia in 16 (41%) and thrombocytopenia in 14 patients (36%). An objective response (best
response) was observed in 33/39 patients (89%; 24 MCL (89%) and 9 FL (90%)), including 14 CR (38%; 12 MCL (36%) and 2 FL
(20%)). Median PFS is 1.5y for MCL and 1.82 years for FL, and median OS has not been reached for either entity. This data
demonstrates promising efficacy of Temsirolimus in r/r MCL and FL with acceptable toxicity. The BeRT regimen may be used as a
treatment option for both entities.
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Introduction
Although improvements in first line and second line treatments
of patientswith follicular lymphoma (FL) ormantle cell lymphoma
(MCL) have been achieved, these lymphomas still are considered
incurable with available conventional strategies.1–4 First line
results to chemoimmunotherapy give reasonable results, however,
if repeated responses typically deteriorate over subsequent
treatment lines. New hope came from the introduction of targeted
agents. Among these new options inhibitors of the mammalian
Target of rapamycin (mTOR) have been explored in different
malignant diseases.5 mTOR is a master switch of protein
translation and a key element of the PI3K/AKT/mTOR pathway.
Activation ofmTORmarkedly enhances themRNA translation of
an important group of growth-related proteins that include cyclin
D1, c-MYC, and hypoxia-inducible factor 1a. Functionally,
mTOR activity increases cellular proliferation as well as growth-
and survival-pathways and inhibits autophagy. mTOR also
regulates the translation of other proteins that are potential
oncogenes contributing to lymphomagenesis (eg, cyclinA, c/EBPb,
and survivin).6,7
Clinically, in lymphoma mTOR inhibitors were primarily
evaluated in MCL based on constitutional overexpression of
cyclin D1. Phase II trials with Temsirolimus, a derivative of
Rapamycin, demonstrated responses in up to 40% of patients
with r/r MCL, and other mTOR-inhibitors have shown similar
results.8–10 A randomized three-arm phase III trial showed dose
dependent superiority of ORR and PFS for Temsirolimus
compared to alternative chemotherapeutic options in rr
MCL,11,12 subsequently resulting in approval. However, com-
plete remissions and long-term remissions are rarely observed
with single agent treatment. Beyond MCL, promising activity of
Temsirolimus has also been demonstrated in other lymphopro-
liferative diseases.13–16 In a phase II study by Smith et al15
evaluating Temsirolimus at a weekly dose of 25mg in patients
with diffuse large B-cell lymphoma an overall response rate of
28% was observed and even more impressive, in r/r FL 54% of
patients achieved an objective response. However, long term
treatments with mTOR inhibitors are associated with cumulative
toxicities, a treatment limitation could therefore be attractive.
The combination of Temsirolimus with Rituximab forMCL has
already been explored, with a notable increase of the overall (59%)
and complete remission rates (19%) as well as progression free
survival in 71 patients.17 In addition, the combination of
Temsirolimus with classical cytotoxic agents, for example,
cladribine18 demonstrates acceptable tolerability and promising
efficacy. Consequently, we aimed to evaluate the triplet of
chemotherapy, monoclonal antibody and Temsirolimus. Bend-
amustine combined with Rituximab (BR) is a worldwide accepted
regimen forMCLandFLwith awell-defined safety profile and19–21
preclinical evidence supports thecombinationwithTemsirolimus.22
Therefore, we initiated a phase I/II trial to firstly explore the
maximum tolerated dose of the Bendamustine, Rituximab, and
Temsirolimus(BeRT)combinationandsecondlyevaluatetheefficacy
of this regimen.Herewereport thefinalanalysisof this trial including
patients from the phase I population and the phase II cohort.
Results
Patients
A total of 39 patients, 28 males and 11 females, entered the
phase I/II trial between 02/2010 and 02/2015. Thereof, 15
patients (11 MCL and 4 FL) were included in the phase I part of
the trial. The characteristics of all enrolled patients are outlined in
Table 1. In brief, median age was 71 years. 29 patients had
relapsed MCL and 10 had FL. The median number of prior
regimens was 2 (range 1–3), and all patients had received
Rituximab treatment prior. Nine patients were pretreated with
Bendamustine and 6 patients had previously received a high dose
therapy. 35% of patients had at partial response or better to their
last treatment line, whereas 60% were refractory (41% with
progressive disease).
Temsirolimus doses, completion of treatment and
relative dose intensity
In phase I each 3 patients were treated at the Temsirolimus 25
mg and 50mg dose level, 6 patients were treated at the 75mg dose
level. All 27 patients in phase II were treated at the 50mg dose
level, therefore 30/39 patients were treated at the recommended
phase II dose.
In total 133 of 156 pre-planned cycles were started (85%) and
101 cycles were completed as planed (65%). The median number
of treatment cycles received was 4 and 27 patients entered the last
cycle period.
The cycle length was on average 31 days (27 to 44 days), in
detail cycle 1: 30.1 days (27 to 42 days), cycle 2: 31.4 days (27
to 42 days), and cycle 3: 31.7 days (27 to 44 days). Taken
together, most cycles were given without any delay, reflected by
a median cycle length of 28 days. Proportional the total number
of cycles started, the following dose intensities were observed:
Rituximab 100%, Bendamustine 99.6% and Temsirolimus
96.8% (Table 2), demonstrating that overall treatment was
well tolerated.
Adverse events (AE)
In all 39 patients who received study treatment at least once,
the following hematologic AEs (any grade) were observed
(number of patients (percentage)) (Table 3): leukopenia in 28
(72%), thrombocytopenia in 25 (64%), neutropenia in 20
(51%), lymphopenia in 16 (41%) and anemia in 11 patients
(28%). Grade 3/4 hematologic adverse events in all treatment
levels and comprising all cycles occurred as follows: leukopenia in
22 (56%), neutropenia in 18 (46%), lymphopenia in 16 (41%)
and thrombocytopenia in 14 patients (36%) (Table 3). Taken
together, 7 patients required at least one erythrocyte transfusion
and 3 patients needed at least one platelet transfusion, G-CSF was
used in 12 patients.
The most frequent non-hematologic treatment emergent
adverse events of any grade were fatigue in 25 (64%), nausea
in 22 (56%), mucositis in 19 (49%), diarrhea and rash in 15
(38%), pyrexia in 14 (36%), constipation in 13 (33%), and
cough in 12 (31%) patients. Grade 3/4 non-hematologic adverse
events were rare and included hyperglycemia in 4 patients (10%)
and angioedema in 2 patients (5%). Any infectious complications
grade 3 or 4 occurred in 9 patients (23%) including stomatitis,
mucositis, and pneumonia.
Efficacy – response rates
Responses were evaluable in 37/39 patients enrolled (Table 4).
The objective response rate for all patients was 89%,with rates of
89% and 90% for MCL and FL, respectively. Complete
remissions were observed in 38% of the entire group, and
Hess et al Bendamustine, Rituximab, Temsirolimus: BeRT for MCL and FL
2
HEMASPHERE-2020-0066; Total nos of Pages: 8;
HEMASPHERE-2020-0066
44% and 20% of MCL and FL patients, respectively. Stable
disease was observed in 11% of the patients, 3 with MCL and 1
patient with FL. If the rate of SD is added to CR/PR, it would
result in a clinical benefit rate of 100%.
Responses were observed early: out of 28 patients
evaluated after 2 cycles, 26 patients had already a partial
remission and 2 complete responses were observed at this time
point.
Progression free survival and overall survival.
At the time of analysis median follow up of all patients was 2.7
years, with the longest follow up of 4.4 years.
Median progression free survival for the entire cohort was 1.6
years (95%CI: 1.08 to 3.55), 1.5 years (95%CI: 0.84 to 3.55) for
patients with MCL and 1.82 years (95% CI: 0.64 to unknown)
for patients with FL (Fig. 1).
Table 1
Patient Characteristics at Inclusion into Trail.
Characteristics MCL (n=29) FL (n=10) Total (n=39)
Age (yr), median (range) 73 (46–79) 68 (48–77) 71 (46–79)
Age >60 years, n (%) 24 (83%) 8 (80%) 32 (82%)
Sex, n (%)
Female 8 (28%) 3 (30%) 11 (28%)
Male 21 (72%) 7 (70%) 28 (72%)
Stage at inclusion, n (%)
I 1 (3%) 0 (0%) 1 (3%)
II 3 (10%) 2 (20%) 5 (13%)
III 4 (14%) 2 (20%) 6 (15%)
IV 21 (72%) 6 (60%) 27 (69%)
Baseline ECOG performance status, n (%)
0 18 (64%) 6 (67%) 24 (65%)
1 10 (36%) 3 (33%) 13 (35%)
2 0 (0%) 0 (0%) 0 (0%)
Baseline FLIPI/MIPI score, n (%)
FLIPI 0-1 2 (2%)
FLIPI 2-3 7 (70%)
FLIPI >3 1 (10%)
MIPI low [0-3] 9 (32%)
MIPI intermediate [4-5] 5 (18%)
MIPI high [> 5] 14 (50%)
Disease stage III/IV, n (%) 25 (86%) 8 (80%) 33 (85%)
Bulky disease
(>7.5 cm), n (%) 5 (18%) 3 (30%) 8 (21%)
Bulky disease (>5.0 cm), n (%) 13 (46%) 7 (70%) 20 (53%)
Elevated LDH 5 (19%) 3 (33%) 8 (23%)
Bone marrow involvement, n (%) 9 (33%) 4 (40%) 13 (35%)
Prior number of regimens (median, range: 2; 1–3)
1 5 (45%) 2 (50%) 7 (47%)
2 2 (18%) 1 (25%) 3 (20%)
≥ 3 4 (36%) 1 (25%) 5 (33%)
Prior radiotherapy, n (%) 1 (3%) 1 (10%) 2 (5%)
Prior stem cell transplantation, n (%) 0 (0%) 2 (20%) 2 (5%)
Prior radio and stem n (%) 2 (7%) 0 (0%) 2 (5%)
Response to most recent prior therapy (26 are available for MCL, 9 for FL)
Complete response (CR) 6 (22%) 1 (10%) 7 (19%)
Partial response (PR) 4 (15%) 2 (20%) 6 (16%)
Stable disease (SD) 4 (15%) 3 (30%) 7 (19%)
Disease progression (PD) 12 (44%) 3 (30%) 15 (41%)










Phase I & Phase II
Total planned dose 1500 mg/m2 720 mg/m2 300/600/900 mg 600 mg
Rel. dose intensity in relation to entire treatment 84.60% 83.50% 78.20% 66.10% 70.70%
Rel. dose intensity in relation to cycles started 100% 99.60% 92.40% 87.40% 89.30%
(2020) 4:3 www.hemaspherejournal.com
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Median overall survival has not been reached for either the
entire group of patients or any subgroup. After 3 years of follow
up 57% of all patients remain alive (Kaplan-Meier estimate),
56% for MCL and 58% for FL (Fig. 2).
Discussion
Novel treatment options have already impacted current
treatment algorithms. Especially in MCL several novel agents
have been successfully introduced, particularly BTK-inhibitors
have significantly changed the current treatment and trial
strategies.23–25 In parallel, other drugs have been successfully
tested, for example, Temsirolimus, Lenalidomid or Bortezomib
and recently Venetoclax,26–31 however, their optimal placement
within treatment sequencing is less clear. In FL Idelalisib, a PI3K
inhibitor, has been approved and other agents of this class are on
their way to clinical practice. Furthermore, Lenalidomide in
combination with Rituximab is a potential alternative relapse
treatement.32
Chemotherapy, although cumbersome, has been shown to
overcome resistance to novel agents33–35 and in addition, offers a
treatment free window for patients in contrast to treatment until
progression with targeted agents. Enhancement of chemotherapy
with novel agents might therefore be a rational strategy to deepen
responses and therefore prolong remission duration and, at the
same time, limit treatment duration. In our trial we evaluated the
combination of BR with Temsirolimus. Overall, we observed
Table 3
Adverse Events, Any Grade and Grades 3/4.
Total
Any grade Grade 3/4
System Organ Class Preferred Term N % N %
Blood and lymphatic system disorder Anemia 11 28 3 8
Leukopenia 28 72 22 56
Lymphopenia 16 41 16 41
Neutropenia 20 51 18 46
Thrombocytopenia 25 64 14 36
Gastrointestinal disorder Constipation 13 33 0 0
Diarrhea 15 38 0 0
Dysphagia 6 15 1 3
Nausea 22 56 0 0
Vomiting 9 23 1 3
Stomatitis 3 8 2 5
General disorders Fatigue 25 64 1 3
Chest pain 5 13 0 0
Chills 6 15 0 0
Mucosal inflammation 19 49 1 3
Oedema peripheral 9 23 0 0
Pyrexia 14 36 1 3
Infections Pneumonia 2 5 2 5
Any infectious complications grade 3/4 32 82 9 23
Investigations Blood lactate dehydrogenase increased 5 13 0 0
Weight decreased 9 23 0 0
Metabolism and nutrition disorders Decreased appetite 10 26 1 3
Hyperglycaemia 6 15 4 10
Hypokalaemia 8 21 3 8
Nervous system disorders Dysgeusia 5 13 0 0
Headache 9 23 0 0
Polyneuropathy 5 13 0 0
Respiratory, thoracic and
mediastinal disorders
Cough 12 31 0 0
Dyspnoe 11 29 2 5
Epistaxis 8 21 0 0
Skin and subcutaneous
tissue disorders
Angioedema 2 5 2 5
Pruritus 6 15 0 0
Rash (generalized, pruritic) 15 38 1 3
Selection: only events grade 3/4 (>5%) or with a frequency > 10% or events of special interest are selected.
Table 4
Response Rates and Progression-free and Overall Survival.
Response MCL (n=29) FL (n=10) Total (n=39)
CR 12 (44%) 2 (20%) 14 (38%)
PR 12 (44%) 7 (70%) 19 (51%)
CR + PR 24 (89%) 9 (90%) 33 (89%)
NE 2 0 2
SD 3 (11%) 1 (10%) 4 (11%)
PD 0 (0%) 0 (0%) 0 (0%)
Median (yr)
PFS 1.46 1.82 (est.) 1.55
OS 3.36 n.r. 3.55 (est.)
CR = complete response, est. = estimated, FL = follicular lymphoma, MCL = mantle cell lymphoma,
n.r. = not reached, OS = overall survival, PD = progressive disease, PFS = progression free survival,
PR = partial response, SD = stable disease.
Hess et al Bendamustine, Rituximab, Temsirolimus: BeRT for MCL and FL
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promising response rates. 89% of MCL and 90% of FL patients
showed at least a partial response and interestingly a substantial
number of CRs (12 MCL (44%); 2 FL (20%)) were observed.
Keeping in mind that BeRT was intended to be a short duration
treatment (only 4 cycles were given), these response rates are
encouraging. Considering that 60% of the study population had
not responded to their individual last treatment line, this
underlines that the combination is able to overcome drug
resistance in a substantial proportion of patients. We noted a
promising duration of progression free and overall survival.
Duration of response was longer in patients with FL; however,
this difference can be expected due to the more indolent nature of
this lymphoma subtype.
If our results are compared to chemo-immunotherapies used
in second line of MCL, they compare favorable to treatments
such as Fludarabin, Cyclophosphamid and Rituximab or
Gemcitabine. Oxaliplatine and Rituximab and compare well
to other Bendamustine-containing combinations.19,36–38 In these
Figure 1. Kaplan-Meier curves of progression-free survival for all patients enrolled. Results for time-to-event end points were analyzed according to
Kaplan-Meier estimator. Median Progression free survival for the entire cohort was 1.6 years. PFS = Progression free survival.
Figure 2. Kaplan-Meier curves of overall survival for all patients enrolled. Results for time-to-event end points were analyzed according to Kaplan-Meier
estimator. After 3 years of follow up 57% of all patients remain alive. OS = Overall survival.
(2020) 4:3 www.hemaspherejournal.com
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trials, the majority of patients had only received 1 prior
treatment line and importantly had been Rituximab naïve in the
majority of cases, which reflects amore adverse risk profile in our
trial. The trial of Visco et al,39,40 BR was combined with
Cytarabinoside and high responses and promising response
durations were observed. However, this treatment showed to
harbor significant toxicities, for example, platelet transfusion are
required in up to 60% to 70% of patients. Thus, this regimen is
restricted to a different population of patients as used in our trial.
Zaja and colleagues evaluated BR plus Lenalidomide41 and it
showed comparable response rates and remission durations –
however, the treatment duration was up to 2 years for
responding patients, which limits comparability. Another trial
evaluating 6 cycles of a similar combination andmaintenance for
8months in first line, demonstrated a high CR rate of 64%42 and
promising median PFS. But substantial side effects were found as
well as a high rate of secondary primary malignancies, limiting
its value especially in younger patients. In comparison to single
targeted agent, with all precautions taken, only results of BTK
inhibitor treatment compares favorable to our results24,25 which
is reflected in current recommendations. Consequently, it would
be of great value to have data available in patients with BTK-
failure. Some agents have shown preliminary but frequently
moderate efficacy in this situation. Lenalidomide was able to
induce remission in 30%32 but duration of response is not
satisfying with only 2 months in median. Venetoclax seems to
induce remissions to a higher extent; however, again PFS is
probably short.43 Therefore, the combination of various novel
agents may become a preferred strategy, foe example, the
combination of Ibrutinib and Venetoclax,44 but if any of these
approaches are moved to frontline, the question of treatment
failure will reappear. As Bendamustine combinations have been
shown to be effective in a substantial number of patients in BTK-
failure,33,45 our data might offer an alternative option in
this scenario.
In FL, novel agents only slowly enter the clinical arena.
Idelalisib is used with precautions only due to its toxicity profile.
In r/r indolent lymphoma patients a median PFS of 11 months
was achieved, but the data cannot be compared to our results, as
the selection criteria differed significantly. The results of
Copanlisib seem equivalent.3 The combination of Lenalidomide
with chemotherapy has been evaluated in various trials46,47 and
recently the results of a randomized trial comparing Lenalido-
mide and Rituximab to Rituximab were shown. PFS was 39
months for patients with FL, however, there is substantial
differences in patient and treatment characteristics, compared to
our trial. Other drugs gave rather disappointing results in
relapsed FL and the number of available options for remains
limited.48,49 Despite our low patient numbers, we find high
response rates and reasonable PFS, importantly better than in the
individual prior treatment line (89% with BERT and 30% with
previous line) and therefore believe our data proves to be
promising for further evaluation.
Furtherwork is needed tomore precisely define the future role of
BeRT15 both in MCL and FL. As the treatment landscape is
evolving rapidly and there are limited options for randomized
comparisons, realworld treatment data baseswill be helpful to give
additional information, which we aim to analyze in the future.
The tolerability of the BeRT treatment was acceptable, with
limited need for transfusion and fatigue being the dominant side
effect. Especially in the phase II part of the trial, after
establishment of the MTD, the rate of side effects remained
reasonable and most patients were able to complete all 4 cycles of
the treatment. However, we did observe that the 3rd dose of
Temsirolimus was occasionally dropped (in 32.4% of FL cases
and in 25.5% of MCL cases) due to moderate thrombocytopenia
which resulted in a relative dose intensity of 87% for
Temsirolimus. As there was no obvious loss of response in
patients with significant thrombocytopenia, this could be a
reasonable approach to maintain cycle intervals stable.
Therefore, given the high response rates, the short treatment
duration and the acceptable side effects profile, we believe that the
results presented here may help to establish the BeRT regimen as
an alternative back up option especially for patients with MCL.
Methods
Conduct of the trial
According to national regulations, the studywas approved by a
harmonized approach of the appropriate Ethic’s Committees and
conducted in accordance with Good Clinical Practice guidelines.
Patients were required to sign informed consent prior to any
study related procedures. Trial conduct was supported by the
IZKS (Interdisciplinary Center for Clinical Trials) of the
University Medical Center Mainz. The trial is registered on
clinicaltrials.gov (NCT01078142).
Study design
This was a prospective multicenter, phase I/II, open-label study
of established regimen for Bendamustine and Rituximab in
combination with Temsirolimus. In the phase I part of the study a
MTD was established, which was defined as published before.50
Patients
For this analysis, patients with r/r follicular (Grade I-IIIA) or
mantle cell lymphoma after one to 3 prior lines of therapy were
considered eligible. In addition, diagnosis of MCL had to be
confirmed by either Cyclin D1 overexpression (immune-histo-
chemistry) or proof of chromosomal translocation t(11;14). A
central pathology review was mandatory.
Main eligibility criteria
Patients with MCL or FL, at least one prior line of treatment
including Rituximab, no curative options available and need for
treatment in FL. Adult patients had to have an Eastern
Cooperative Group (ECOG) performance status of 0–2, an
appropriate hematopoietic reserve (absolute neutrophil count
≥1500/mL; platelets ≥75,000/mL) as well as liver (aspartate
aminotransferase (AST) and alanine aminotransferase (ALT)
<2.5 times ULN, total bilirubin <1.5 times the upper limit of
normal (ULN)) and renal function (creatinine clearance > 50ml/
min). Disease manifestation had to be measurable (≥ 1 disease
lesion >1.5cm  1.0cm or bone marrow infiltration). No prior
allogeneic stem cell transplantation was allowed.
Treatment regimen
The BeRT regimen consisted of Bendamustine given at a dose
of 90mg/m2 i.v. day 1 and 2 every 4 weeks, Rituximab 375mg/
m2 i.v. was given on day 0 or 1. After establishment of a
maximum tolerated dose in the first part of this study,
Temsirolimus was given at a dose of 50mg i.v. on day 2, 8,
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15 of a 4 week cycle. A total of 4 treatment cycles was planned, as
this had been shown to be efficacious and safe in preceding
trials.19,38 G-CSF use was up to the investigator’s discretion.
Adverse events were graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03.
Evaluations
All patients starting study treatment in phase I and phase II
were included in the safety population, and efficacy analyses
were performed in all patients enrolled on an intent-to-treat
(ITT) basis.
Response to treatment was defined according to the 2007
international response criteria for non Hodgkin lymphoma.50
Initial staging included CT-scans of neck, chest, abdomen and
pelvis and radiological evaluation of all affected regions. Re-
staging was scheduled after 2 and 4 cycles and every 3 months for
the first 12 months, followed by 6-months intervals thereafter.
PFS was defined as time from treatment start to date of relapse or
refractoriness, disease progression or death, or censored at the
last tumor evaluation date. OS was measured as time from first
dose to date of death or censored at the last date of patient
contact. After progression or the initiation of a new therapy,
patients were followed with respect to survival.
Objectives and statistical analysis
Phase I defined the MTD of BeRT whereas efficacy was the
primary aim of the phase II part of the study.
The primary endpoint was the objective response rate (number
of patients with PR and CR) in patients with mantle cell or
follicular lymphoma treated at the maximum tolerated dose of
BERT. Secondary endpoints were the rate of side effects observed,
overall response rate (CR, PR), progression free survival (PFS),
duration of response, time to subsequent lymphoma therapy,
treatment free interval and overall survival (OS). Due to the
explorative character, no formal sample size calculation was
performed. However,Wald’s sequential probability ratio test was
applied to exclude that the number of no-responders exceeded a
critical value.
Results for time-to-event endpoints were analyzed according to
Kaplan-Meier estimator. SAS Version 9.4. (SAS Institute, Cary,
NJ) was used for all calculations.
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